Claim Details: Submit your information here: https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-incinvestigation. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. To speak with an attorney for more information visit: Why Bleichmar Fonti & Auld LLP? https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation N ...

NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. BFA is currently investigating the go private transaction and believes that Cerevel Therapeutics' board of directors was conflicted, engag ...

Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichm ...

Core Viewpoint - Cerevel Therapeutics (CERE) is being acquired by AbbVie (ABBV) for $45 per share, totaling approximately $8.7 billion, which is seen as beneficial for both companies and their shareholders [2][5][15] - The deal is currently under review by the FTC, with expectations that it will close by the end of the year, presenting a potential short-term arbitrage opportunity for investors [2][4][15] Company Overview - CERE was established as a spinout from Pfizer's CNS pipeline assets, with a focus on developing drugs for schizophrenia, Parkinson's disease, and epilepsy [2][4] - The lead assets include emraclidine for schizophrenia, tavapadon for Parkinson's, and darigabat for epilepsy, with emraclidine being the primary value driver due to its potential market size [4][6][8] Financials - CERE had approximately $1.065 billion in cash at the end of March 2024, with a burn rate of about $96.9 million per quarter, indicating financial stability to continue operations if the deal is delayed [9] - The acquisition price of $45 per share represents a significant premium over CERE's stock price prior to the announcement, which closed at $40.74 on May 31, 2024, indicating a potential upside of over 10% for investors [2][3][15] Market Context - AbbVie is seeking to enhance its CNS portfolio, which is currently overshadowed by its immunology products, particularly Humira, which generated $18 billion in sales in 2023 [5][12] - The urgency for AbbVie to replace potential revenue losses from Humira, which is facing biosimilar competition, has driven the acquisition strategy, including the purchase of CERE [5][12] Regulatory Environment - The FTC is conducting a review of the acquisition, requesting additional information, which is not typical for deals of this size, leading to speculation about potential market overlaps [4][10] - Historical precedents of similar acquisitions, such as ABBV's purchase of ImmunoGen and Bristol Myers Squibb's acquisition of Karuna Therapeutics, suggest that the CERE deal may ultimately be approved [10][11] Competitive Landscape - CERE's emraclidine faces competition from other CNS drugs, including ABBV's own Vraylar, which could influence the FTC's review process [6][12] - The competitive dynamics in the CNS space, particularly for schizophrenia treatments, are complex, with multiple companies developing similar assets [6][10] Conclusion - The acquisition of CERE by AbbVie is positioned as a strategic move to bolster AbbVie's CNS capabilities while providing CERE shareholders with a profitable exit [2][5][15] - Investors are advised to consider the potential for a short-term gain of approximately 10% as the deal progresses through regulatory scrutiny [2][3][15]

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, Ab ...

PHILADELPHIA, May 30, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf of the company's shareholders. On December 6, 2023, Cerevel announced that it had agreed to be acquired by AbbVie Inc. at a price of $45.00 per share in cash. Following the closing of the proposed transaction, Cerevel's current stockholders will be cashed out of their investment position and the company's shares will no longer be publicly trad ...

Next Steps: NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of ...

PHILADELPHIA, May 20, 2024 /PRNewswire/ -- Shareholder protection law firm Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf of the company's investors. On December 6, 2023, Cerevel announced that it had agreed to be acquired by AbbVie Inc. at a price of $45.00 per share in cash. Following the closing of the proposed transaction, Cerevel's current stockholders will be cashed out of their investment position and the company's shares wi ...

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transac ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from _________________ to _________________ Commission File Number: 001-39311 CEREVEL THERAPEUTICS HOLDINGS, INC. (Exact name of Registrant as specified in its Cha ...